Latest news
Gilead’s HIV PrEP franchise hits $1B quarterly sales, but analysts question Yeztugo durability - Fierce PharmaFierce Pharma · Wed, 05 Aug 2026 14:44:51 GMTDrugmakers don’t have ‘duty to innovate’, California court rules, backing Gilead in HIV drug litigation - Fierce PharmaFierce Pharma · Tue, 04 Aug 2026 19:00:00 GMTAtea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trial - Fierce BiotechFierce Biotech · Tue, 28 Jul 2026 13:08:59 GMT